The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer
Published version of a preprint
Abstract
HER3 is overexpressed in several cancers, including colorectal cancer. Although therapies with anti-HER3 antibodies have been investigated, significant clinical benefits have not been reported. U3-1402 is a novel HER3-antibody–drug conjugate (ADC) composed of the HER3 antibody patritumab and a novel topoisomerase I inhibitor, DX-8951 derivative (DXd). The sensitivity of DXd was evaluated by a growth inhibition assay. The antitumor activity of U3-1402 was evaluated in a murine xenograft model in which its effects on cells, with a range of HER3 expression levels, were compared with those of patritumab alone, irinotecan, control-ADC, and saline. In the growth inhibition assay, all colorectal cancer cell lines were sensitive to DXd. In the tumor xenograft model, significant tumor regression with U3-1402 was observed both in the DiFi cell line (high HER3 expression; KRAS wild type) and in SW620 (high HER3 expression; KRAS mutation), but no treatment effect was observed in Colo320DM (low HER3 expression). Notably, SW620 tumor growth was significantly suppressed with U3-1402 compared with the saline-treated group (P < 0.001) and showed greater activity compared with the irinotecan group. By contrast, patritumab alone, control-ADC, and saline did not significantly differ in tumor growth inhibition. The antitumor activity of U3-1402 was dependent on HER3 expression level, but not on KRAS mutation status. These results support further investigation of development strategies for U3-1402 in patients with HER3-expressing colorectal cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Currently, HER3-targeted drugs U3-1402 [30], lumretuzumab [76] and MEHD7945A [77] have been used in preclinical and clinical trials with good safety and efficacy.”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [30]
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · cited 1×
“Colorectal cancer is a major cause of cancer death worldwide (1).”
BackgroundPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer
Sauer, R., Becker, H., Hohenberger, W., Rödel, C., Wittekind, C., Fietkau, R., Martus, P., Tschmelitsch, J., Hager, E., Hess, C. F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040694 · Cited by 6,050 · cited 3×
“Therefore, HER3-targeted therapies have been developed (24, 25); however, monoclonal antibody against HER3, such as patritumab, or dualtarget monoclonal antibodies against EGFR/HER3, such as duligotuzumab, have not shown any significant clinical benefit in mCRC patients in early clinical trials (26, 27).”
BackgroundMET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496 · cited 1×
“HER3 signaling is also associated with the resistance mechanism of anti-EGFR/HER2 therapies in several malignancies (21-23).”
BackgroundCetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 1×
“therapy with anti-HER2 antibody (trastuzumab) and lapatinib have shown activity in patients with KRAS codon 12/13 wild-type/HER2 positive mCRC in clinical trials (12-14).”
BackgroundTrastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834 · cited 1×
“Although ADC development has been driven by hematologic cancers (28–30), a new approach with HER2-targeted ADCs, such as trastuzumab emtansine or trastuzumab deruxtecan, has led to breakthrough results in solid tumors (31, 32), or with other targeted ADCs has shown promising results in preclinical study (33–37), and i…”
BackgroundOxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Zaninelli, M., Clingan, P., Bridgewater, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,689 · cited 3×
“Therefore, HER3-targeted therapies have been developed (24, 25); however, monoclonal antibody against HER3, such as patritumab, or dualtarget monoclonal antibodies against EGFR/HER3, such as duligotuzumab, have not shown any significant clinical benefit in mCRC patients in early clinical trials (26, 27).”
BackgroundK-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622 · cited 3×
“Therefore, HER3-targeted therapies have been developed (24, 25); however, monoclonal antibody against HER3, such as patritumab, or dualtarget monoclonal antibodies against EGFR/HER3, such as duligotuzumab, have not shown any significant clinical benefit in mCRC patients in early clinical trials (26, 27).”
BackgroundWild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 3×
“Therefore, HER3-targeted therapies have been developed (24, 25); however, monoclonal antibody against HER3, such as patritumab, or dualtarget monoclonal antibodies against EGFR/HER3, such as duligotuzumab, have not shown any significant clinical benefit in mCRC patients in early clinical trials (26, 27).”
BackgroundDe Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144 · cited 3×
“Therefore, HER3-targeted therapies have been developed (24, 25); however, monoclonal antibody against HER3, such as patritumab, or dualtarget monoclonal antibodies against EGFR/HER3, such as duligotuzumab, have not shown any significant clinical benefit in mCRC patients in early clinical trials (26, 27).”
Background
Cited by
Jänne, P. A., Baik, C., Su, W.-C., Johnson, M. L., Hayashi, H., Nishio, M., Kim, D.-W., Koczywas, M., Gold, K. A., Steuer, C. E., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0715 · Cited by 289
Antibody–drug conjugates in solid tumors: a look into novel targets
Criscitiello, C., Morganti, S., & Curigliano, G. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01035-z · Cited by 250
Yu, H. A., Goto, Y., Hayashi, H., Felip, E., Chih-Hsin Yang, J., Reck, M., Yoh, K., Lee, S.-H., Paz-Ares, L., Besse, B., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01476 · Cited by 246
Precision medicine for human cancers with Notch signaling dysregulation (Review)
Katoh, M., & Katoh, M. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4418 · Cited by 191
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Metadata
- Authors
- Koganemaru, S., Kuboki, Y., Koga, Y., Kojima, T., Yamauchi, M., Maeda, N., Kagari, T., Hirotani, K., Yasunaga, M., Matsumura, Y., & Doi, T.
- Affiliations
- Keio University (JP)
- National Cancer Center Hospital East (JP)
- National Cancer Centre Japan (JP)
- Daiichi-Sankyo (Japan) (JP)
- ORCID
- Venue
- Molecular Cancer Therapeutics
- Published
- 2019-11-01
- Volume
- 18
- Issue
- 11
- Pages
- 2043-2050
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2969010216
- Cited by
- 90
- References
- 55
- Citations by year
- 2026: 5 · 2025: 14 · 2024: 20 · 2023: 18 · 2022: 13 · 2021: 13 · 2020: 6 · 2019: 1
- FWCI
- 3.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Cancer Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Daiichi Sankyo Company (Sankyo Company)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- HER3, antibody-drug conjugates, patritumab, topoisomerase I inhibitor, colorectal cancer, KRAS mutation, irinotecan, tumor xenografts, anticancer activity
- MeSH terms
- Broadly Neutralizing Antibodies, Animals, Camptothecin, Cell Survival, Female, Humans, Colorectal Neoplasms, Up-Regulation, Gene Expression Regulation, Neoplastic, Immunoconjugates, Receptor, ErbB-3, Xenograft Model Antitumor Assays, HCT116 Cells, Cell Line, Tumor, Cell Proliferation, Mice, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer. https://app.cochat.ai/papers/10.1158/1535-7163.mct-19-0452
- The paper
- Koganemaru, S., Kuboki, Y., Koga, Y., Kojima, T., Yamauchi, M., Maeda, N., Kagari, T., Hirotani, K., Yasunaga, M., Matsumura, Y., & Doi, T. (2019). U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-19-0452
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.